Is it time to say goodbye to weekly rituximab in ANCA vasculitis?

被引：0
|
作者：
Pinto, Benzeeta [1 ]
Dhooria, Aadhaar [2 ]
机构：
[1] St Johns Med Coll, Dept Clin Immunol & Rheumatol, Sarjapur Rd, Bengaluru 560034, India
[2] Santokba Durlabhji Mem Hosp, Dept Clin Immunol & Rheumatol, Jaipur, Rajasthan, India
来源：
CLINICAL RHEUMATOLOGY | 2020年 / 39卷 / 10期
关键词：
CYCLOPHOSPHAMIDE;
D O I：
10.1007/s10067-020-05360-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3153 / 3154
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial
    Geetha, Duvuru
    Dua, Anisha
    Yue, Huibin
    Springer, Jason
    Salvarani, Carlo
    Jayne, David
    Merkel, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (02) : 223 - 232
  • [42] Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited
    Bensalem, Amina
    Mulleman, Denis
    Paintaud, Gilles
    Azzopardi, Nicolas
    Gouilleux-Gruart, Valerie
    Cornec, Divi
    Specks, Ulrich
    Ternant, David
    CLINICAL PHARMACOKINETICS, 2020, 59 (04) : 519 - 530
  • [43] Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort
    Chasseur, P.
    Blockmans, D.
    von Frenckell, C.
    Nicolas, J-B.
    Regniers, C.
    Vandergheynst, F.
    ACTA CLINICA BELGICA, 2020, 75 (03) : 163 - 169
  • [44] PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
    van Dam, Laura S.
    Dirikgil, Ebru
    Bredewold, Edwin W.
    Ray, Argho
    Bakker, Jaap A.
    van Kooten, Cees
    Rabelink, Ton J.
    Teng, Yoe K. Onno
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (08) : 1408 - 1417
  • [45] A case of COVID-19-associated C-ANCA vasculitis, was successfully treated with rituximab therapy
    Filoramo, Michael
    Contractor, Renish
    Chandramohan, Deepak
    Singh, Prabhat
    Jena, Nihar
    Simhadri, Prathap Kumar
    CLINICAL CASE REPORTS, 2024, 12 (08):
  • [46] Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis
    Nagafuchi, Hiroko
    Atsumi, Tatsuya
    Hatta, Kazuhiro
    Muso, Eri
    Takeno, Mitsuhiro
    Yamada, Hidehiro
    Ozaki, Shoichi
    MODERN RHEUMATOLOGY, 2015, 25 (04) : 603 - 608
  • [47] Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study
    Podesta, Manuel Alfredo
    Mescia, Federica
    Ricchiuto, Anna
    Smith, Rona
    Tedesco, Martina
    Cassia, Matthias Arnaldo
    Holle, Julia
    Sinico, Renato Alberto
    Bruchfeld, Annette
    Gunnarsson, Iva
    Ohlsson, Sophie
    Baslund, Bo
    Hruskova, Zdenka
    Tesar, Vladimir
    Sabiu, Gianmarco
    Gallieni, Maurizio
    Cid, Maria C.
    Vaglio, Augusto
    Harper, Lorraine
    Cozzolino, Mario
    Scolari, Francesco
    Jayne, David
    Alberici, Federico
    RHEUMATOLOGY, 2023, 62 (08) : 2850 - 2854
  • [48] Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?
    Tesar, Vladimir
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (07) : 1088 - 1090
  • [49] Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary
    Tieu, Joanna
    Smith, Rona
    Basu, Neil
    Brogan, Paul
    D'Cruz, David
    Dhaun, Neeraj
    Flossmann, Oliver
    Harper, Lorraine
    Jones, Rachel B.
    Lanyon, Peter C.
    Luqmani, Raashid A.
    McAdoo, Stephen P.
    Mukhtyar, Chetan
    Pearce, Fiona A.
    Pusey, Charles D.
    Robson, Joanna C.
    Salama, Alan D.
    Smyth, Lucy
    Watts, Richard A.
    Willcocks, Lisa C.
    Jayne, David R. W.
    RHEUMATOLOGY, 2020, 59 (04) : 727 - 731
  • [50] ANCA-ASSOCIATED VASCULITIS
    Vandergheynst, F.
    ACTA CLINICA BELGICA, 2013, 68 (06) : 406 - 410
12345